

ZETAMAX™

(Azithromycin)

1. NAME OF THE MEDICINAL PRODUCT

ZETAMAX™

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Capsules: Azithromycin dihydrate 262.05 mg equivalent to 250 mg azithromycin base.

Powder for Oral Suspension: Azithromycin dihydrate 209.64 mg/5 ml equivalent to 200 mg/5 ml of azithromycin base.

Film-coated Tablet 250 mg: Azithromycin dihydrate 262.05 mg equivalent to 250 mg azithromycin base.

Film-coated Tablet 500 mg: Azithromycin dihydrate 524.10 mg equivalent to 500 mg azithromycin base.

3. PHARMACEUTICAL FORM

Capsules: Azithromycin capsules for oral administration are available as plain white No. 0 hard gelatin capsules containing azithromycin dihydrate equivalent to 250 mg azithromycin.

Powder for Oral Suspension: Azithromycin powder for oral suspension is presented as a dry powder, which yields, on reconstitution with water, a white to off-white suspension containing the equivalent of 200 mg azithromycin per 5 ml.

Film-coated Tablets: Azithromycin film-coated tablets are capsular shaped and contain azithromycin dihydrate equivalent to 250 mg or 500 mg azithromycin.

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

Azithromycin is indicated for infections caused by susceptible organisms; in lower respiratory tract infections including bronchitis and pneumonia, in odontostomatological infections,⁽¹⁴²⁾ in skin and soft tissue infections, in acute otitis media and in upper respiratory tract infections including sinusitis and pharyngitis/tonsillitis.

(Penicillin is the usual drug of choice in the treatment of *Streptococcus pyogenes* pharyngitis, including the prophylaxis of rheumatic fever. Azithromycin is generally effective in the eradication of streptococci from the oropharynx; however, data establishing the efficacy of azithromycin and the subsequent prevention of rheumatic fever are not available at present.)^(2,70-73)

In sexually transmitted diseases in men and women, ZETAMAX™ is indicated for the treatment of uncomplicated genital infections due to *Chlamydia trachomatis*. It is also indicated for the treatment of

chancroid due to *Haemophilus ducreyi*⁽¹³⁶⁻¹³⁸⁾ and uncomplicated genital infections due to non-multiresistant *Neisseria gonorrhoeae*; concurrent infection with *Treponema pallidum* should be excluded.^(27,70,74,75)

ZETAMAX™ is indicated, either alone or in combination with rifabutin, for prophylaxis against *Mycobacterium avium*-intracellulare complex (MAC) infection, an opportunistic infection prevalent in patients with advanced human immunodeficiency virus (HIV).⁽¹²²⁾

ZETAMAX™ is indicated in combination with ethambutol for the treatment of disseminated MAC (DMAC) infection in patients with advanced HIV infection.⁽¹⁴³⁾

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

ZETAMAX™ should be administered as a single daily dose. The period of dosing with regard to infection is given below.

Administration of ZETAMAX™ capsules following a substantial meal reduces bioavailability by at least 50%. Therefore, in common with many other antibiotics, each dose of the capsules should be taken at least 1 hour before or 2 hours after food.⁽⁸⁴⁾

ZETAMAX™ tablets and powder for oral suspension can be taken with or without food.⁽¹⁴⁵⁾

In adults

For the treatment of sexually transmitted diseases caused by *Chlamydia trachomatis* and *Haemophilus ducreyi*,⁽¹³⁶⁻¹³⁸⁾ the dose is 1000 mg as a single oral dose.^(27,57,75) For susceptible *Neisseria gonorrhoeae*, the recommended dose is 1000 mg or 2000 mg of azithromycin in combination with 250 mg or 500 mg ceftriaxone according to local clinical treatment guidelines. For patients who are allergic to penicillin and/or cephalosporins, prescribers should consult local treatment guidelines.⁽²²⁶⁾

For prophylaxis against MAC infections in patients infected with the HIV, the dose is 1200 mg once per week.⁽¹²²⁾

For the treatment of DMAC infections in patients with advanced HIV infection, the recommended dose is 600 mg once a day. Azithromycin should be administered in combination with other antimycobacterial agents that have shown *in vitro* activity against MAC, such as ethambutol, at the approved dose.⁽¹⁴³⁾

For all other indications in which the oral formulation is administered, the total dosage of 1500 mg should be given as 500 mg daily for 3 days. As an alternative, the same total dose can be given over 5 days with 500 mg given on Day 1, then 250 mg daily on Days 2 to 5.⁽⁸³⁾

In children

The maximum recommended total dose for any treatment is 1500 mg for children.^(146,147)

In general, the total dose in children is 30 mg/kg. Treatment for pediatric streptococcal pharyngitis should be dosed at a different regimen (see below).⁽⁹²⁾

The total dose of 30 mg/kg should be given as a single daily dose of 10 mg/kg daily for 3 days, or given over 5 days with a single daily dose of 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.⁽⁹²⁾

As an alternative to the above dosing, treatment for children with acute otitis media can be given as a single dose of 30 mg/kg.⁽¹⁴⁸⁻¹⁵¹⁾

For pediatric streptococcal pharyngitis, azithromycin given as a single dose of 10 mg/kg or 20 mg/kg for 3 days has been shown to be effective; however, a daily dose of 500 mg must not be exceeded.^(146,147) In clinical trials comparing these two dosage regimens, similar clinical efficacy was observed but greater bacteriologic eradication was evident at the 20 mg/kg/day dose. However, penicillin is the usual drug of choice for the treatment of *Streptococcus pyogenes* pharyngitis, including prophylaxis of rheumatic fever.⁽¹⁴⁰⁾

For children weighing less than 15 kg, ZETAMAXTM suspension should be measured as closely as possible. For children weighing 15 kg or more, ZETAMAXTM suspension should be administered according to the guide provided below.⁽⁹²⁾

ZETAMAXTM Suspension 30 mg/kg Total Treatment Dose			
Weight (kg)	3-Day Regimen	5-Day Regimen	Bottle Size (mg)
<15	10 mg/kg once daily on Days 1-3	10 mg/kg on Day 1, then 5 mg/kg once daily on Days 2-5	600
15-25	200 mg (5 ml) once daily on Days 1-3	200 mg (5 ml) on Day 1, then 100 mg (2.5 ml) once daily on Days 2-5	600
26-35	300 mg (7.5 ml) once daily on Days 1-3	300 mg (7.5 ml) on Day 1, then 150 mg (3.75 ml) once daily on Days 2-5	900
36-45	400 mg (10 ml) once daily on Days 1-3	400 mg (10 ml) on Day 1, then 200 mg (5 ml) once daily on Days 2-5	1200
>45	Dose as per adults	Dose as per adults	1500

ZETAMAXTM capsules or tablets should only be administered to children weighing more than 45 kg.

Safety and efficacy for the prevention or treatment⁽¹⁴³⁾ of MAC in children have not been established. Based on pediatric pharmacokinetic data, a dose of 20 mg/kg would be similar to the adult dose of 1200 mg but with a higher C_{max}.⁽¹²²⁾

Special populations

In the Elderly

The same dosage as in adult patients is used in the elderly. Elderly patients may be more susceptible to the development of *torsades de pointes* arrhythmia than younger patients^(55,224) (see section 4.4 **Special Warnings and Precautions for Use**).

In Patients with Renal Impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10-80 ml/min). Caution should be exercised when ZETAMAXTM is administered to patients with severe renal impairment

(GFR<10 ml/min)⁽¹⁵²⁾ (see section **4.4 Special Warnings and Precautions for Use** and section **5.2 Pharmacokinetic Properties**).

In Patients with Hepatic Impairment

The same dosage as in patients with normal hepatic function may be used in patients with mild to moderate hepatic impairment⁽⁸⁶⁾ (see section **4.4 Special Warnings and Precautions for Use**).

4.3. CONTRAINDICATIONS

The use of this product is contraindicated in patients with a hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any excipient listed in section **6.1 List of Excipients**.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Hypersensitivity

As with erythromycin and other macrolides, rare serious allergic reactions, including angioedema and anaphylaxis (rarely fatal),⁽¹⁰¹⁾ Dermatologic reactions, including Acute Generalized Exanthematous Pustulosis (AGEP),⁽²³²⁾ Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) (rarely fatal),⁽²²⁴⁾ and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)^(228,234) have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment.⁽⁸⁵⁾

If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.⁽²²⁴⁾

Hepatotoxicity

Since liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease.⁽⁸⁶⁾

Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.⁽²²⁴⁾

Infantile hypertrophic pyloric stenosis (IHPS)

Following the use of azithromycin in neonates (treatment up to 42 days of life), infantile hypertrophic pyloric stenosis (IHPS) has been reported. Parents and caregivers should be informed to contact their physician if vomiting or irritability with feeding occurs.⁽²³⁰⁾

Ergot derivatives

In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be co-administered.^(227,229)

Superinfection

As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms, including fungi is recommended.

Clostridium difficile-associated diarrhea

Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of *C. difficile*.⁽¹⁸⁵⁻¹⁹⁸⁾

C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.⁽¹⁸⁵⁻¹⁹⁸⁾

Renal impairment

In patients with severe renal impairment (GFR <10 ml/min), a 33% increase in systemic exposure to azithromycin was observed⁽¹⁵²⁾ (see section **5.2 Pharmacokinetic Properties**).

Diabetes

Azithromycin 40 mg/ml powder for oral suspension: Caution in diabetic patients: 5 ml of reconstituted suspension contains 3.87 g of sucrose.

Due to the sucrose content (3.87 g/5 ml of reconstituted suspension), this medicinal product is not indicated for persons with fructose intolerance (hereditary fructose intolerance), glucose-galactose malabsorption or saccharase-isomaltase deficiency.⁽²⁰⁰⁾

Prolongation of the QT interval

Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and *torsades de pointes*, have been seen in treatment with macrolides, including azithromycin^(179,180,224) (see section **4.8 Undesirable Effects**). Prescribers should consider the risk of QT prolongation, which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including⁽²²⁵⁾:

- Patients with congenital or documented QT prolongation⁽²²⁴⁾
- Patients currently receiving treatment with other active substances known to prolong QT interval such as antiarrhythmics of Classes IA and III, antipsychotic agents, antidepressants, and fluoroquinolones⁽²²⁴⁾
- Patients with electrolyte disturbance, particularly in cases of hypokalemia and hypomagnesemia⁽²²⁴⁾
- Patients with clinically relevant bradycardia, cardiac arrhythmia or cardiac insufficiency⁽²²⁴⁾
- Elderly patients: elderly patients may be more susceptible to drug-associated effects on the QT interval⁽²²⁴⁾

Myasthenia gravis⁽²³¹⁾

- Exacerbations of the symptoms of myasthenia gravis have been reported in patients receiving azithromycin therapy.

4.5. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION**Antacids**

In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with azithromycin, no effect on overall bioavailability was seen, although peak serum concentrations were reduced by approximately 24%.⁽²²⁷⁾ In patients receiving both azithromycin and antacids, the drugs should not be taken simultaneously.⁽⁷⁹⁾

Cetirizine

In healthy volunteers, co-administration of a 5-day regimen of azithromycin with 20 mg cetirizine at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.⁽¹⁵³⁾

Didanosine (Dideoxyinosine)

Co-administration of 1200 mg/day azithromycin with 400 mg/day didanosine in six HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of didanosine as compared to placebo.^(122,175)

Digoxin and colchicine²³⁵

Concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-glycoprotein substrates⁽²¹⁶⁾ such as digoxin are administered concomitantly, the possibility of elevated serum digoxin concentrations should be considered.⁽²¹⁶⁾ Clinical monitoring, and possibly serum digoxin levels, during treatment with azithromycin and after its discontinuation are necessary.⁽²²⁴⁾

Ergot

There is a theoretical possibility of interaction between azithromycin and ergot derivatives^(78,227,229) (see section 4.4 **Special Warnings and Precautions for Use**).

Zidovudine

Single 1000 mg doses and multiple 1200 mg or 600 mg doses of azithromycin had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.^(90,91,174)

Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin.⁽¹⁵⁴⁻¹⁵⁷⁾

Pharmacokinetic studies have been conducted between azithromycin and the following drugs known to undergo significant cytochrome P450-mediated metabolism.⁽¹⁵⁴⁻¹⁵⁷⁾

Atorvastatin

Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay).⁽¹⁵⁸⁾

However, post-marketing cases of rhabdomyolysis in patients receiving azithromycin with statins have been reported.⁽²²³⁾

Carbamazepine

In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin.^(78,88)

Cimetidine

In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin pharmacokinetics was seen.⁽⁸⁰⁾

Coumarin-type oral anticoagulants

In a pharmacokinetic interaction study, azithromycin did not alter the anticoagulant effect of a single dose of 15-mg warfarin administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral anticoagulants.^(77,135)

Cyclosporin

In a pharmacokinetic study with healthy volunteers who were administered a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of cyclosporin, the resulting cyclosporin C_{max} and AUC_{0-5} were found to be significantly elevated. Consequently, caution should be exercised before considering concurrent administration of these drugs. If co-administration of these drugs is necessary, cyclosporin levels should be monitored and the dose adjusted accordingly.^(78,93)

Efavirenz

Co-administration of a single dose of 600 mg azithromycin and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions.^(143,177)

Fluconazole

Co-administration of a single dose of 1200 mg azithromycin did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of azithromycin were unchanged by the co-administration of fluconazole; however, a clinically insignificant decrease in C_{max} (18%) of azithromycin was observed.⁽¹⁵⁹⁾

Indinavir

Co-administration of a single dose of 1200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.⁽¹⁶⁰⁾

Methylprednisolone

In a pharmacokinetic interaction study in healthy volunteers, azithromycin had no significant effect on the pharmacokinetics of methylprednisolone.⁽⁸⁹⁾

Midazolam

In healthy volunteers, co-administration of 500 mg/day azithromycin for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single dose of 15 mg midazolam.⁽¹⁶¹⁾

Nelfinavir

Co-administration of azithromycin (1200 mg) and nelfinavir at steady-state (750 mg three times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects were observed and no dose adjustment was required.⁽¹⁶²⁾

Rifabutin

Co-administration of azithromycin and rifabutin did not affect the serum concentrations of either drug.^(122,176)

Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with azithromycin has not been established^(122,176) (see section **4.8 Undesirable Effects**).

Sildenafil

In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC and C_{max} of sildenafil or its major circulating metabolite.⁽¹⁶³⁾

Terfenadine

Pharmacokinetic studies have reported no evidence of an interaction between azithromycin and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however, there was no specific evidence that such an interaction had occurred.^(95,100)

Theophylline

There is no evidence of a clinically significant pharmacokinetic interaction when azithromycin and theophylline are co-administered to healthy volunteers.^(76,87,181)

Triazolam

In 14 healthy volunteers, co-administration of 500 mg azithromycin on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo.⁽¹⁶⁴⁾

Trimethoprim/sulfamethoxazole

Co-administration of trimethoprim/sulfamethoxazole DS (160 mg/800 mg) for 7 days with 1200 mg azithromycin on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies.⁽¹⁶⁵⁾

4.6. FERTILITY, PREGNANCY AND LACTATION

Pregnancy

Animal reproduction studies have been performed at doses up to moderately maternally toxic dose concentrations. In these studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.⁽¹⁸³⁾

Lactation

Limited information available from published literature indicates that azithromycin is present in human milk at an estimated highest median daily dose of 0.1 to 0.7 mg/kg/day. No serious adverse effects of azithromycin on the breast-fed infants were observed.⁽²³³⁾

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from azithromycin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.^(224,233)

Fertility

In fertility studies conducted in rats, reduced pregnancy rates were noted following administration of azithromycin. The relevance of this finding to humans is unknown.⁽²²⁴⁾

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

There is no evidence to suggest that azithromycin may have an effect on a patient's ability to drive or operate machinery.

4.8. UNDESIRABLE EFFECTS

ZETAMAX™ (azithromycin) is well tolerated with a low incidence of side effects.⁽⁸²⁾

In clinical trials, the following undesirable effects have been reported:

Blood and Lymphatic System Disorders: Transient episodes of mild neutropenia have occasionally been observed in clinical trials.⁽⁸³⁾

Ear and Labyrinth Disorders: Hearing impairment (including hearing loss,⁽¹²⁰⁾ deafness⁽¹²⁰⁾ and/or tinnitus⁽¹²⁰⁾) has been reported in some patients receiving azithromycin. Many of these have been associated with prolonged use of high doses in investigational studies. In those cases where follow-up information was available, the majority of these events were reversible.⁽⁹⁶⁾

Gastrointestinal Disorders: Nausea,⁽⁸²⁾ vomiting,⁽⁸²⁾ diarrhea,⁽⁸²⁾ loose stools,⁽⁸²⁾ abdominal discomfort (pain/cramps),⁽⁸²⁾ and flatulence.⁽⁸²⁾

Hepatobiliary Disorders: Abnormal liver function.⁽⁸²⁾

Skin and Subcutaneous Tissue Disorders: Allergic reactions⁽⁸⁵⁾ including rash⁽⁸⁵⁾ and angioedema.⁽⁸⁵⁾

General Disorders and Administration Site Conditions: Local pain and inflammation at the site of infusion.⁽¹⁴⁴⁾

The following undesirable effects have been reported in association with DMAC prophylaxis and treatment clinical trials:

The most frequent (>5% in any treatment group) adverse reactions in HIV-infected patients receiving azithromycin for prophylaxis for DMAC were diarrhea, abdominal pain, nausea, loose stools, flatulence, vomiting, dyspepsia, rash, pruritus, headache, and arthralgia.⁽¹⁶⁶⁾

When 600 mg azithromycin is given daily for the treatment of DMAC infection for prolonged periods, the most frequently reported treatment-related side effects are abdominal pain, nausea, vomiting, diarrhea, flatulence, headache, abnormal vision, and hearing impairment.⁽¹⁴³⁾

In post-marketing experience, the following additional undesirable effects have been reported:

Infections and Infestations: Moniliasis⁽¹²⁷⁾ and vaginitis.⁽¹³⁴⁾

Blood and Lymphatic System Disorders: Thrombocytopenia.⁽¹³²⁾

Immune System Disorders: Anaphylaxis⁽⁸⁵⁾ (rarely fatal)⁽¹⁰¹⁾ (see section 4.4 **Special Warnings and Precautions for Use**).

Metabolism and Nutrition Disorders: Anorexia.⁽¹¹⁰⁾

Psychiatric Disorders: Aggressive reaction,⁽¹²³⁾ nervousness,⁽¹²⁸⁾ agitation,⁽¹²⁴⁾ and anxiety.⁽¹²⁵⁾

Nervous System Disorders: Dizziness,⁽¹⁰⁴⁾ convulsions,⁽¹⁰⁶⁾ headache,⁽¹⁰⁷⁾ hyperactivity,⁽¹²⁶⁾ hypoesthesia,⁽¹⁹⁹⁾ paresthesia,⁽¹⁰⁹⁾ somnolence,⁽¹⁰⁸⁾ and syncope.⁽¹⁶⁸⁾

There have been rare reports of taste/smell perversion and/or loss.^(121,131,184)

Ear and Labyrinth Disorders: Deafness, tinnitus, hearing impaired,⁽²²⁴⁾ and vertigo⁽¹⁰⁵⁾.

Cardiac Disorders: Palpitations⁽¹⁰²⁾ and arrhythmias including ventricular tachycardia⁽¹⁰³⁾ have been reported. There have been rare reports of QT prolongations and *torsades de pointes*.⁽¹⁸⁰⁾ (see section 4.4 **Special Warnings and Precautions for Use**).

Vascular Disorders: Hypotension.⁽¹⁶⁷⁾

Gastrointestinal Disorders: Vomiting⁽⁸²⁾/diarrhea⁽⁸²⁾ (rarely resulting in dehydration), dyspepsia,⁽¹¹¹⁾ constipation,⁽¹¹²⁾ pseudomembranous colitis,⁽¹³⁰⁾ pancreatitis,⁽¹⁶⁹⁾ and rare reports of tongue discoloration.⁽¹³³⁾

Hepatobiliary Disorders: Hepatitis⁽¹¹⁵⁾ and cholestatic jaundice^(97,98) have been reported, as well as rare cases of hepatic necrosis and hepatic failure, which have resulted in death⁽¹³⁹⁾ (see section 4.4 **Special Warnings and Precautions for Use, Hepatotoxicity**).

Skin and Subcutaneous Tissue Disorders: Allergic reactions⁽⁸⁵⁾ including pruritus,⁽¹²⁹⁾ rash,⁽⁸⁵⁾ photosensitivity,⁽⁹⁹⁾ edema,⁽¹¹⁷⁾ urticaria,⁽¹¹⁸⁾ and angioedema.⁽⁸⁵⁾ Rarely, serious cutaneous adverse reactions including erythema multiforme, AGEP,⁽²³²⁾ SJS, TEN,⁽¹¹⁹⁾ and DRESS^(228,234) have been reported.

Musculoskeletal and Connective Tissue Disorders: Arthralgia.⁽¹¹⁶⁾

Renal and Urinary Disorders: Interstitial nephritis⁽¹¹⁴⁾ and acute renal failure.⁽¹¹⁴⁾

General Disorders and Administration Site Conditions: Asthenia,⁽¹¹³⁾ fatigue,⁽¹⁷⁰⁾ and malaise.⁽¹⁷¹⁾

4.9. OVERDOSE

Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required.⁽¹⁴¹⁾

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Macrolides, ATC code J01FA.

Mode of action

Azithromycin is the first of a subclass of macrolide antibiotics, known as azalides, and is chemically different from erythromycin.⁽¹⁵⁴⁻¹⁵⁷⁾ Chemically it is derived by insertion of a nitrogen atom into the lactone ring of erythromycin A. The chemical name of azithromycin is 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0.⁽¹⁻⁴⁾

Azithromycin binds to the 23S rRNA of the 50S ribosomal subunit. It blocks protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit.⁽²²⁴⁾

Cardiac electrophysiology

QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.⁽²²⁵⁾

Mechanism of resistance

The two most frequently encountered mechanisms of resistance to macrolides, including azithromycin, are target modification (most often by methylation of 23S rRNA) and active efflux. The occurrence of these resistance mechanisms varies from species to species and, within a species, the frequency of resistance varies by geographical location.

The most important ribosomal modification that determines reduced binding of macrolides is post-transcriptional (N₆)-dimethylation of adenine at nucleotide A2058 (*Escherichia coli* numbering system) of the 23S rRNA by methylases encoded by *erm* (erythromycin ribosome methylase) genes.⁽²²⁴⁾ Ribosomal modifications often determine cross-resistance (MLS_B phenotype) to other classes of antibiotics whose ribosomal binding sites overlap those of the macrolides: the lincosamides (including clindamycin), and the streptogramin B (which include, for example, the quinupristin component of quinupristin/dalfopristin). Different *erm* genes are present in different bacterial species, in particular streptococci and staphylococci.⁽²²⁴⁾ Susceptibility to macrolides can also be affected by less frequently encountered mutational changes in nucleotides A2058 and A2059, and at some other positions of 23S rRNA, or in the large subunit ribosomal proteins L4 and L22.⁽²²⁴⁾

Efflux pumps occur in a number of species, including gram-negatives, such as *Haemophilus influenzae* (where they may determine intrinsically higher minimal inhibitory concentrations [MICs]) and staphylococci.⁽²²⁴⁾ In streptococci and enterococci, an efflux pump that recognizes 14- and 15-membered macrolides (which include, respectively, erythromycin and azithromycin) is encoded by *mef*(A) genes.

Methodology for determining the *in vitro* susceptibility of bacteria to azithromycin

Susceptibility testing should be conducted using standardized laboratory methods, such as those described by the Clinical and Laboratory Standards Institute (CLSI). These include dilution methods (MIC determination) and disk susceptibility methods. Both CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) provide interpretive criteria for these methods.

Based on a number of studies, it is recommended that the *in vitro* activity of azithromycin be tested in ambient air to ensure physiological pH of the growth medium.⁽²²⁴⁾ Elevated CO₂ tensions, as often used for streptococci and anaerobes, and occasionally for other species, result in a reduction in the pH of the medium. This has a greater adverse effect on the apparent potency of azithromycin than on that of other macrolides.⁽²²⁴⁾

The CLSI susceptibility breakpoints, based on broth microdilution or agar dilution testing, with incubation in ambient air, are given in the table below.

CLSI Dilution Susceptibility Interpretive Criteria			
Organism	Broth microdilution MIC (mg/L)		
	Susceptible	Intermediate	Resistant
<i>Haemophilus</i> species	≤4	-	- ^b
<i>Moraxella catarrhalis</i>	≤0.25	-	-
<i>Neisseria meningitidis</i>	≤2	-	- ^b
<i>Staphylococcus aureus</i>	≤2	4	≥8
Streptococci ^a	≤0.5	1	≥2

^a Includes *Streptococcus pneumoniae*, β-hemolytic streptococci and viridans streptococci.
^b The current absence of data on resistant strains precludes defining any category other than susceptible. If strains yield MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.⁽²¹⁸⁾
 Incubation in ambient air.
 CLSI = Clinical and Laboratory Standards Institute; MIC = Minimal inhibitory concentration.
 Source: CLSI M45, 2015.⁽²¹⁸⁾ CLSI M100, 2018.⁽²¹⁹⁾

Susceptibility can also be determined by the disk diffusion method, measuring inhibition zone diameters after incubation in ambient air. Susceptibility disks contain 15 µg of azithromycin. Interpretive criteria for inhibition zones, established by the CLSI on the basis of their correlation with MIC susceptibility categories, are listed in the table below.

CLSI Disk Zone Interpretive Criteria			
Organism	Disk inhibition zone diameter (mm)		
	Susceptible	Intermediate	Resistant
<i>Haemophilus</i> species	≥12	-	-
<i>Moraxella catarrhalis</i>	≥26	-	-
<i>Neisseria meningitidis</i>	≥20	-	-
<i>Staphylococcus aureus</i>	≥18	14 - 17	≤13
Streptococci ^a	≥18	14 - 17	≤13

^a Includes *Streptococcus pneumoniae*, β-hemolytic streptococci and viridans streptococci.
 Incubation in ambient air.
 CLSI = Clinical and Laboratory Standards Institute;
 mm = Millimeters.
 Source: CLSI M45, 2015.⁽²¹⁸⁾ CLSI M100, 2018.⁽²¹⁹⁾

The validity of both the dilution and disk diffusion test methods should be verified using quality control (QC) strains, as indicated by the CLSI. Acceptable limits when testing azithromycin against these organisms are listed in the table below.

Quality Control Ranges for Azithromycin Susceptibility Tests	
Broth microdilution MIC	
Organism	Quality control range (mg/L azithromycin)
<i>Haemophilus influenzae</i> ATCC 49247	1-4
<i>Staphylococcus aureus</i> ATCC 29213	0.5-2
<i>Streptococcus pneumoniae</i> ATCC 49619	0.06-0.25
Disk inhibition zone diameter (15 µg disk)	
Organism	Quality control range (mm)
<i>Haemophilus influenzae</i> ATCC 49247	13-21
<i>Staphylococcus aureus</i> ATCC 25923	21-26
<i>Streptococcus pneumoniae</i> ATCC 49619	19-25

Quality Control Ranges for Azithromycin Susceptibility Tests	
Broth microdilution MIC	
Organism	Quality control range (mg/L azithromycin)
Incubation in ambient air.	
CLSI = Clinical and Laboratory Standards Institute; MIC = Minimal inhibitory concentration;	
mm = Millimeters	
Source: CLSI M100, 2018 ⁽²¹⁹⁾	

EUCAST has also established susceptibility breakpoints for azithromycin based on MIC determination. The EUCAST susceptibility criteria are listed in the table below.

EUCAST Susceptibility Breakpoints for Azithromycin		
	MIC (mg/L)	
	Susceptible	Resistant
<i>Staphylococcus</i> species	≤1	>2
<i>Streptococcus pneumoniae</i>	≤0.25	>0.5
β-hemolytic streptococci ^a	≤0.25	>0.5
<i>Haemophilus influenzae</i>	≤0.12	>4
<i>Moraxella catarrhalis</i>	≤0.25	>0.5
<i>Neisseria gonorrhoeae</i>	≤0.25	>0.5

^a Includes Groups A, B, C, G.
EUCAST = European Committee on Antimicrobial Susceptibility Testing; MIC = Minimal inhibitory concentration.
Source: EUCAST Web site.
EUCAST Clinical Breakpoint Table v. 8.0, valid from 2018-01-01
www.eucast.org/.../EUCAST.../Breakpoint_tables/v_8.0_Breakpoint_Tables.pdf⁽²¹⁷⁾

Antibacterial spectrum

The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Azithromycin demonstrates cross-resistance with erythromycin-resistant gram-positive isolates. As discussed above, some ribosomal modifications determine cross-resistance with other classes of antibiotics whose ribosomal binding sites overlap those of the macrolides: the lincosamides (including clindamycin) and the streptogramin B (which include, for example, the quinupristin component of quinupristin/dalfopristin). A decrease in macrolide susceptibility over time has been noted in particular in *Streptococcus pneumoniae* and *Staphylococcus aureus*, and has also been observed in viridans streptococci and *Streptococcus agalactiae*.⁽²²⁴⁾

Organisms that are commonly susceptible to azithromycin include:

Aerobic and facultative gram-positive bacteria (erythromycin-susceptible isolates): *S. aureus*, *Streptococcus agalactiae*,* *S. pneumoniae*,* *Streptococcus pyogenes*,* other β-hemolytic streptococci (Groups C, F, G), and viridans streptococci. Macrolide-resistant isolates are encountered relatively frequently among aerobic and facultative gram-positive bacteria, in particular among methicillin-resistant *S. aureus* (MRSA) and penicillin-resistant *S. pneumoniae* (PRSP).

Aerobic and facultative gram-negative bacteria: *Bordetella pertussis*, *Campylobacter jejuni*, *Haemophilus ducreyi*,* *Haemophilus influenzae*,* *Haemophilus parainfluenzae*,* *Legionella pneumophila*, *Moraxella catarrhalis*,* and *Neisseria gonorrhoeae**. *Pseudomonas* spp. and most *Enterobacteriaceae* are

inherently resistant to azithromycin, although azithromycin has been used to treat *Salmonella enterica* infections.⁽²²⁴⁾

Anaerobes: *Clostridium perfringens*, *Peptostreptococcus* spp. and *Prevotella bivia*.

Other bacterial species: *Borrelia burgdorferi*, *Chlamydia trachomatis*, *Chlamydophila pneumoniae*,* *Mycoplasma pneumoniae*,* *Treponema pallidum*, and *Ureaplasma urealyticum*.

Opportunistic pathogens associated with HIV infection: MAC* and the eukaryotic microorganisms *Pneumocystis jirovecii* and *Toxoplasma gondii*.

*The efficacy of azithromycin against the indicated species has been demonstrated in clinical trials.

5.2. PHARMACOKINETIC PROPERTIES

Absorption

Following oral administration in humans, azithromycin is widely distributed throughout the body; bioavailability is approximately 37%. Administration of azithromycin capsules following a substantial meal reduces bioavailability by at least 50%. The time taken to peak plasma levels is 2 to 3 hours.^(54,56-58)

Distribution

In animal studies, high azithromycin concentrations have been observed in phagocytes. In experimental models, higher concentrations of azithromycin are released during active phagocytosis than from non-stimulated phagocytes. In animal models, this results in high concentrations of azithromycin being delivered to the site of infection.⁽⁶³⁻⁶⁶⁾

Pharmacokinetic studies in humans have shown markedly higher azithromycin levels in tissues than in plasma (up to 50 times the maximum observed concentration in plasma), indicating that the drug is heavily tissue bound. Concentrations in target tissues, such as lung, tonsil and prostate, exceed the MIC₉₀ for likely pathogens after a single dose of 500 mg.^(17,56-61)

Following oral administration of daily doses of 600 mg azithromycin, C_{max} was 0.33 µg/ml and 0.55 µg/ml at Day 1 and Day 22, respectively. Mean peak concentrations observed in leukocytes, the major site of disseminated MAC infection, were 252 µg/ml (±49%) and remained above 146 µg/ml (±33%) for 24 hours at steady-state.⁽¹⁷²⁾

Elimination

Plasma terminal elimination half-life closely reflects the tissue depletion half-life of 2 to 4 days. Approximately 12% of an intravenously administered dose is excreted in the urine over 3 days as the parent drug, the majority in the first 24 hours. Biliary excretion of azithromycin is a major route of elimination for unchanged drug following oral administration. Very high concentrations of unchanged drug have been found in human bile, together with 10 metabolites, formed by N- and O-demethylation, hydroxylation of the desosamine and aglycone rings, and cleavage of the cladinose conjugate. Comparison of HPLC and microbiological assays in tissues suggests that metabolites play no part in the microbiological activity of azithromycin.^(54,58,62,178)

Pharmacokinetics in special patient groups

Elderly

In elderly volunteers (>65 years), slightly higher AUC values were seen after a 5-day regimen than in young volunteers (<40 years), but these are not considered clinically significant, and hence no dose adjustment is recommended.⁽⁵⁵⁾

Renal Impairment

The pharmacokinetics of azithromycin in subjects with mild to moderate renal impairment (GFR 10 - 80 ml/min) were not affected following a single 1 gram dose of immediate-release azithromycin. Statistically significant differences in AUC₀₋₁₂₀ (8.8 µg·h/ml vs. 11.7 µg·h/ml), C_{max} (1.0 µg/ml vs. 1.6 µg/ml) and CL_r (2.3 ml/min/kg vs. 0.2 ml/min/kg) were observed between the group with severe renal impairment (GFR <10 ml/min) and the group with normal renal function.⁽¹⁵²⁾

Hepatic Impairment

In patients with mild (Class A) to moderate (Class B) hepatic impairment, there is no evidence of a marked change in serum pharmacokinetics of azithromycin compared to those with normal hepatic function. In these patients, urinary clearance of azithromycin appears to increase, perhaps to compensate for reduced hepatic clearance.⁽⁸⁶⁾

5.3. PRECLINICAL SAFETY DATA

Phospholipidosis (intracellular phospholipid accumulation) has been observed in several tissues (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) of mice, rats, and dogs given multiple doses of azithromycin. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs. The effect has been shown to be reversible after cessation of azithromycin treatment. The significance of the finding for animals and humans is unknown.⁽¹⁸³⁾

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

- **Capsules:** The capsules contain anhydrous lactose, maize starch, magnesium stearate, and sodium lauryl sulfate as excipients. The capsule shell contains gelatin, titanium dioxide (E171) and up to 1000 ppm sulfur dioxide.
- **Powder for Oral Suspension:** The powder for oral suspension contains sucrose (1.94 g per 100 mg dose), sodium phosphate tribasic anhydrous, hydroxypropyl cellulose, xanthan gum, artificial cherry, creme de vanilla and banana flavors.
- **Film-coated Tablets:** The tablets contain pregelatinized starch, calcium phosphate dibasic anhydrous, croscarmellose sodium, magnesium stearate and sodium lauryl sulfate. The film coating contains hydroxypropyl methylcellulose, triacetin and titanium dioxide (E171).

6.2. INCOMPATIBILITIES

Not available

6.3. SHELF LIFE

- **Capsules:** 2 years.
- **Powder for Oral Suspension:** 2 years for the dry powder and 5 days for the reconstituted product.
- **Film-coated Tablets:** 2 years.

6.4. SPECIAL PRECAUTIONS FOR STORAGE

- **Capsules:** Store below 30°C. Protect from light and moisture.
- **Powder for Oral Suspension:** Store below 30°C for the powder and the reconstituted suspension.
- **Film-coated Tablets:** Store below 30°C.

6.5. NATURE AND CONTENT OF CONTAINER

- **Capsules:** The capsules are packed in the PVC blister packs.
- **Powder for Oral Suspension:** The powder for oral suspension is packed in high density polyethylene bottles.
- **Film-coated Tablets:** The tablets are packed in the following container systems:
 - a) Opaque PVC blister packs
 - b) Clear PVC blister packs
 - c) Polyethylene bottles

6.6. SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

Capsules: The capsules should be swallowed whole.

Powder for Oral Suspension: Tap the bottle to loosen the powder. To the 600 mg bottle, add 9 ml of water; to the 900 mg bottle add 12 ml of water; to the 1200 mg bottle add 15 ml of water; and to the 1500 mg bottle add 19 ml of water. Shake well. Shake immediately prior to use.

For children weighing less than 15 kg, the suspension should be measured as closely as possible. For children weighing 15 kg or more, the suspension should be administered using an appropriate measuring device.

Film-coated Tablets: The tablets should be swallowed whole.

Zetamax/LPD/PK10

According to CDS V 17.0 Dated: May-02, 2018; Supersedes CDS V 16.0 Dated: March-26, 2018

Manufactured by:
Pfizer Pakistan Limited
B-2, S.I.T.E., Karachi

Marketed By:
Pfizer Pakistan Limited
B-2, S.I.T.E., Karachi

7. REFERENCES

1. Azithromycin IRD. Vol 2.1. March 1990; Pharmaceutical Data: pp. 18, 30.
2. English AR, Girard AE, Cimoehowski C, Faiella J, Retsema JA. *In-vivo* studies with CP-62,993/XZ-450, a new macrolide with an extended half-life and tissue distribution (abstract). In: Programs and Abstracts of the Twenty Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 28 Sept-1 Oct 1986. Washington, DC, American Society for Microbiology 1986; 267.
3. Bright GM, Nagel AA, Bordner J, *et al.* Synthesis, *in-vitro* and *in-vivo* activity of novel 9-deoxo-9a-aza-9a homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. *J Antibiotic* 1988;8:1029-1047.
4. Prous JR (ed). Azithromycin. *Drugs Future* 1988;13-9-12.
7. Azithromycin IRD. Vol 3.8. March 1990; Pharmacodynamics: p. 1921-1922.
8. Aranoff SC, Laurent C, Jacobs MR. Comparison of the activity of three macrolides, erythromycin, RU 28965, and CP-62,993, against common pediatric pathogens (abstract). In: Programs and Abstracts of the Twenty Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 28 Sept-1 Oct 1986. Washington, DC, American Society for Microbiology 1986; 267.
9. Aranoff SC, Laurent C, Jacobs MR. *In-vitro* activity of erythromycin, roxithromycin, and CP-62,993 against common pediatric pathogens (letter). *J Antimicrob Chemother* 1987;19:275-276.
10. Retsema JA, Girard AE, Schelkly WU, Manousos M, Anderson M, Bright G, Borovey R, Brennan L, Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. *Antimicrob Agents Chemother* 1987;31:1939-1947.
11. Dunkin KT, Jones C, Howard AJ. The *in-vitro* activity of CP-62,993 against *Haemophilus influenzae*, *Branhamella catarrhalis*, *Staphylococci*, and *Streptococci*. *J Antimicrob Chemother* 1988;21:405-411.
12. Chin NX, Saha G, Labthavikul P, Neu HC. The *in-vitro* activity of CP-62,993, a new 15-membered-ring macrolide compared with that of other oral antibiotics (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;136.
13. Hardy DJ, Hensey DM, Beyer JM, Vogtko C, McDonald EJ, Fernandes PB. Comparative *in-vitro* activities of new 14-, 15-, and 16-membered macrolides. *Antimicrob Agents Chemother* 1988;32:1710-1719.
14. Fernades PB, Hardy DJ. Comparative *in-vitro* potencies of nine new macrolides. *Drugs Exp Clin Res* 1988;14:445-451.
15. Neu HC, Chin NX, Saha G, Labthavikul P. Comparative *in-vitro* activity of the new oral macrolide azithromycin. *Eur J Clin Microbiol Infect Dis* 1988;7:541-544.

16. Goldstein FW, Emirian MF, Coutrot A, Acar JF. Bacteriostatic and bactericidal activity of CP-62,993 against *Haemophilus influenzae* (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;136.
17. Ryan FW, Kwansik I, Tilton RC. In-vitro activity of the macrolide CP-62,993/XZ-450 against selected micro-organisms (abstract). In: Programs and Abstracts of the Twenty Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 28 Sept-1 Oct 1986. Washington, DC, American Society for Microbiology 1986; 267.
18. Yourassowski E, Van der Linden MP, Lismont MJ, Crokaert F, Glupezynski Y. Rate of bactericidal activity for *Branhamella catarrhalis* of new macrolide CP-62,993, compared with of amoxicillin-clavulanic acid. *Chemotherapy* 1988;34:191-194.
19. Girard AE, Retsema JA, Girard D. Relationship of tissue levels and bactericidal activity to oral efficacy of azithromycin (CP-62,993/XZ-450) in middle ear and tissue infection models (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;138.
20. Jones K, Felmingham D, Ridgway G. In-vitro activity of azithromycin (CP-62,993), a novel macrolide against enteric pathogens. *Drugs Exp Clin Res* 1988;14:613-615.
21. Hoppe JE, Eichorn A. Activity of new macrolides against *Bordetella pertussis* and *Bordetella parapertussis*. *Eur J Clin Microbiol Infect Dis* 1980;8:653-654.
22. Tambic T, Djokic S, Davila D, Kolacny-Babic L. Erythromycin series 14. Antibacterial activity of 15-membered macrolide antibiotic azithromycin. *Acta Pharm Yugosl* 1989;39:233-237.
23. Kitzis MD, Goldstein FW, Miegli M, Acar JF. In-vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria. *J Antimicrob Chemother* 1990;25(Suppl A):15-18.
24. Girard AE, Girard D, English AR, Gootz TD, Cimochoowski CR, Faiella JA, Haskell SL, Retsema JA. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. *Antimicrob Agents Chemother* 1987;31:54.
25. Slancy L, Plummer F, Ronald AR, Degagne P, Hoban D, Brunham RC. In-vitro activity of azithromycin against *Neisseria gonorrhoeae*, *Haemophilus ducreyi*, and *Chlamydia trachomatis* (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;136.
26. Slancy L, Plummer F, Ronald AR, Degagne P, Hoban D, Brunham RC. In-vitro activity of azithromycin (CP-62,993) against *Neisseria gonorrhoeae*, *Haemophilus ducreyi*, and *Chlamydia trachomatis*. *J Chemother Infect Dis Malignancies Suppl* 1:1989:401.
27. Steingrimsson O, Olafsson J, Thorarinsson H, Ryan R, Johnson R, Tilton R. Azithromycin (CP-62,993): an innovative approach to the problem of sexually transmitted disease (abstract). *J Chemother Infect Dis Malignancies* 1980; Suppl 1:409.

28. Walsh M, Kappus EW, Quinn TC. In-vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against *Chlamydia trachomatis*. *Antimicrob Agents Chemother* 1987;31:811-812.
29. Ridgway GL. Antimicrobial chemotherapy of Chlamydial infection: where next? *Eur J Clin Microbiol* 1986;5:550-553.
30. Slancy L, Chubb H, Ronald A, Brunham R. In-vitro activity of azithromycin, erythromycin, ciprofloxacin, and norfloxacin against *Neisseria gonorrhoeae*, *Haemophilus ducreyi*, and *Chlamydia trachomatis*. *J Antimicrob Chemother* 1990; 2581-2585.
31. Scieux C, Branchi A, Choppey B, Vassias I, Perol Y. In-vitro activity of azithromycin against *Chlamydia trachomatis*. *J Antimicrob Chemother* 1990(Suppl A):25:7-10.
32. Stamm LV, Parrish EA. In-vitro activity of azithromycin and CP-63,956 against *Treponema pallidum*. *J Antimicrob Chemother* 1990; 25 (Suppl A):11-14.
33. Raskine L, Honderlick P, Casin I, Sanson-Le Purs MJ. In-vitro activity of three new macrolide antibiotics and one new quinolone against strains of *Haemophilus ducreyi* isolated in Paris. In: Programs and Abstracts of the Twenty Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, 17-20 Sept 1989. Washington, DC, American Society for Microbiology 1989:1282.
34. Lukehart SA, Fohn MJ, Baker-Zander SA. Efficacy of azithromycin (CP-62,993) for active syphilis infection in the rabbit model (abstract). *J Chemother Infect Dis Malignancies* 1989; Suppl 1:406.
35. Lukehart SA, Fohn MJ, Baker-Zander SA. Efficacy of CP-62,993 for active syphilis infection in the rabbit model (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;138.
36. Bermudez LEM, Kolonoski P, Petrofsky ML, Young LS. Treatment of *Mycobacterium avium* infections in-vivo and in-vitro with a combination of immunomodulators and antibiotics. In: 89th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, 14-18 May 1989. American Society for Microbiology 1989;163.
37. Kolonoski PT, Martinelli J, Petrofsky ML, Wu M, Inderlied CB. Azithromycin and clofazimine combinations for disseminated *Mycobacterium avium* complex infection in C57 beige mice. In: 89th Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, 14-18 May 1989;325.
38. Kolonoski PT, Wu M, Petrofsky ML, Martinelli J, Young LS, Inderlied CB. Combinations of amikacin, azithromycin, and clofazimine for the treatment of disseminated *Mycobacterium avium* complex infection in beige mice (abstract). In: Programs and Abstracts of the Twenty Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, 17-20 Sept 1989. Washington, DC, American Society for Microbiology 1989:325.
39. Naik S, Ruck R. In-vitro activity of several new macrolide antibiotics against *Mycobacterium avium* complex. *Antimicrob Agents Chemother* 1989;33:1614-1616.

40. Schonwald S, Gunjaca M. Comparison of azithromycin (CP-62,993/XZ-450) and erythromycin in the treatment of atypical pneumonias (abstract). *J Chemother Infect Dis Malignancies* 1989; Suppl 1:407.
41. Chirgivin K, Roblin PM, Hammerslag MR. In-vitro susceptibilities of *Chlamydia pneumoniae* (*Chlamydia* sp. strain TWAR). *Antimicrob Agents Chemother* 1989;33:1634-1635.
42. Johnson RC, Kodner C, Reessel M. In-vitro and in-vivo susceptibility of *Borrelia burgdorferi* to three antimicrobial agents (abstract). *J Chemother Infect Dis Malignancies* 1989; Suppl 1:399.
43. Johnson RC, Kodner C, Russel M. In-vitro and in-vivo susceptibility of *Borrelia burgdorferi* to three antimicrobial agents (abstract). In: *Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy*, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;138.
44. Johnson RC, Kodner C, Russel M, Duray PH. Experimental infection of the hamster with *Borrelia burgdorferi*. *Ann New York Acad Sci* 1988;539:258-263.
45. Rylander M, Hallander HO. In-vitro comparison of the activity of doxycycline, tetracycline, erythromycin, and a new macrolide, CP-62,993, against *Mycoplasma pneumoniae*, *Mycoplasma hominis*, and *Ureaplasma urealyticum*. *Scand J Infect Dis* 1988;53(Suppl):12-17.
46. Czinn S, Carr H, Aronoff S. Susceptibility of *Campylobacter pyloridis* to three macrolide antibiotics [erythromycin, roxithromycin (RU 28965), and CP-62,993] and rifampin. *Antimicrob Agents Chemother* 1986;30:328-329.
47. Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of *Campylobacter pylori* to macrolides and fluoroquinolones. *J Antimicrob Chemother* 1988;22:631-636.
48. Inderlied CB, Kolonski PK, Wu M, Young LS. Azithromycin: an effective therapeutic agent for disseminated *Mycobacterium avium* infection in the beige mouse. *Ann Clin Lab Sci* 1988; 18:413-414.
49. Inderlied CB, Kolonski PK, Wu M, Young LS. In-vitro and in-vivo activity of azithromycin (CP-62,993) against the *Mycobacterium avium* complex [published erratum appears in *J Infect Dis* 1989;160(6):1095]. *J Infect Dis* 1989;159:994-997.
50. Barry AL, Jones RN, Thornsberry C. In-vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. *Antimicrob Agents Chemother* 1988;32:752-754.
51. Araujo FG, Guptill DR, Remington JS. Azithromycin, a macrolide antibiotic with potent activity against *Toxoplasma gondii*. *Antimicrob Agents Chemother* 1988;32:755-757.
52. Chang HR, Pechere JC. In-vitro effects of four macrolides [roxithromycin, spiramycin, azithromycin (CP-62,993), and A-56268] on *Toxoplasma gondii*. *Antimicrob Agents Chemother* 1988;32:524-529.
53. Araujo FG, Remington JS. Further studies on the activity of azithromycin against *Toxoplasma gondii* (abstract). *J Chemother Infect Dis Malignancies* 1989; Suppl 1:411.

54. Azithromycin IRD. Vol 4.2. March 1990; Study Report 007. Phase I Multiple-Dose Safety and Pharmacokinetic Study of CP-62,993. p. 117-155. Dated 9 February 1990.
55. Azithromycin IRD. Vol 4.3. March 1990; Study Report 212. An open study to compare the pharmacokinetics, safety and toleration of a multiple dose regimen of Azithromycin between healthy young and healthy elderly volunteers. p. 322-372. Dated 3 January 1990.
56. Foulds G, Shepard RM. Tissue and serum kinetics of azithromycin in man (abstract). J Chemother Infect Dis Malignancies 1980; Suppl 1:402.
57. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; Suppl A:73-82.
58. Shepard RM, Wedler DJ, Gary DC, Madsen PO, Cox CE, Chan KH, Bluestone CD. Human pharmacokinetics of azithromycin (CP-62,993/XZ-450), a new macrolide with an extended half-life and high tissue penetration (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987; 138.
59. Girard AE, Girard D, Retsema JA, Shepard RM. Importance of azithromycin's (CP-62,993) extravascular pharmacokinetics in *in-vivo* efficacy (abstract). In: Programs and Abstracts of the Twenty Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif., 23-26 Oct 1988. Washington, DC, American Society for Microbiology 1988; 248.
60. Girard AE, Girard D, Retsema JA. Correlation of the impressive extravascular pharmacokinetics of azithromycin with *in-vivo* efficacy in model of localized infection (abstract). J Chemother Infect Dis Malignancies 1989; Suppl 1:404.
61. Shepard RM, Falkner FC. Pharmacokinetics in rats and dogs of azithromycin, (CP-62,993), a novel azalide antibiotic with a long half-life and high tissue penetration (abstract). J Chemother Infect Dis Malignancies 1989; Suppl 1:401.
62. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin (CP-62,993) and erythromycin A (abstract). In: Programs and Abstracts of the Twenty Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 4-7 Oct 1987. Washington, DC, American Society for Microbiology 1987;36.
63. Gladue RP, Bright GM, Newborg MF. *In-vitro* and *in-vivo* uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection (abstract). In: Programs and Abstracts of the Twenty Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif., 23-26 Oct 1988. Washington, DC, American Society for Microbiology 1988;234.
64. Gladue RP, Bright GM, Newborg MF. *In-vitro* and *in-vivo* uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection (abstract). J Chemother Infect Dis Malignancies 1989; Suppl 1:405.
65. Gladue RP, Bright GM, Isaacson RE, Newborg MF. *In-vitro* and *in-vivo* uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282.

66. Wildfeuer A, Laufen H, Muller-Wening D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. *Arzneimittel-Forschung* 1989;39:755-758.
67. Azithromycin IRD. Vol 3.1. March 1990; Pharmacol Tox Expert Report. p. 15-18, 374-377.
68. Azithromycin IRD. Vol 4.2. March 1990; Clinical Study Report 008. Phase I multiple dose open comparative study of Azithromycin and erythromycin ethylsuccinate for assessment of pharmacokinetics and neurological and audiometric safety in healthy male volunteers. p. 156-321.
69. Azithromycin IRD. Vol 4.5. March 1990; Clinical Study Report 011. Phase I multiple dose study to determine the presence of Azithromycin in cerebrospinal fluid and to assess peripheral blood lymphocytes for phospholipid accumulation. p. 1019-1058.
70. Lassus A. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by *Neisseria* and *Chlamydia* species. *J Antimicrob Chemother* 1990; 25(Suppl A):115-121.
71. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Goser M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. *J Antimicrob Chemother* 1990; 25(Suppl A):123-126.
72. Chan KH, Swarts JD, Doyle WJ, Tampowpong K, Kardatzke DR. Efficacy of a new macrolide (azithromycin) for acute otitis media in the chinchilla model. *Arch Otolaryngol Head Neck Surg* 1988; 114:1266-1269.
73. Chan KH, Swarts JD, Doyle WJ, Tampowpong K, Kardatzke DR. Efficacy of the prototype azalide, azithromycin (CP-62,993), in acute otitis media (abstract). *J Chemother Infect Dis Malignancies* 1989; Suppl 1:408.
74. Steingrimmson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. *J Antimicrob Chemother* 1990;25(Suppl A):109-114.
75. Azithromycin IRD. Vol 4.1. March 1990; Clinical Expert Report. p. 18-20.
76. Azithromycin IRD. Vol 4.4. March 1990; Study Report 213. An open study in healthy volunteers to assess the pharmacokinetic interaction between Azithromycin and theophylline. p. 682-722.
77. Azithromycin IRD. Vol 4.4. March 1990; Study Report 214. A single-blind study in healthy volunteers to assess the pharmacological interaction between Azithromycin and warfarin. p. 723-754.
78. Azithromycin IRD. Vol 4.1. March 1990; Clinical Expert Report. p. 10.
79. Study Report 015: Phase I Study of the Effect of Concomitant Antacid Administration on the Absorption on Azithromycin. Gerber, Nicholas, MB, BS. IRD Azithromycin (Azithromax) Capsules and Powder for Oral Suspension, Part 4/Volume 4.4 of 4, March 1990, p. 618-649.

80. Azithromycin IRD. Vol 4.4. March 1990; Study Report 016. Phase I study of the effect of concomitant cimetidine administration on the absorption of Azithromycin. p. 650-681.
81. Azithromycin IRD. Vol 3.1. March 1990; Pharmacol Tox Expert Report. p. 23, 30, 405-406, 425.
82. Azithromycin IRD. Vol 4.1. Overall Clinical Summary. p. 159-164.
83. Azithromycin IRD. Vol 4.1. March 1990; Clinical Expert Report. p. 25-26.
84. Azithromycin IRD. Vol 4.1. March 1990; Clinical Expert Report. p. 7-8.
85. Azithromycin Case Summaries: L-1N892, L-7S792, and L-1S792.
86. Study AZM-I-90-001: Open non-comparative study on the safety, toleration, and pharmacokinetics of azithromycin in the treatment of adult patients with hepatic insufficiency following oral administration of a single dose.
87. Study 228: A double-blind, placebo-controlled, parallel group study to investigate the effect of orally administered azithromycin on the plasma concentration profile of theophylline.
88. Study 221: A double-blind, placebo-controlled, parallel group study to investigate the effect of orally administered azithromycin on the plasma concentration profiles of carbamazepine and its epoxide metabolite in healthy volunteers.
89. Study 218: A double-blind, placebo-controlled study to investigate the effect of orally administered azithromycin (500 mg x 1 day, 250 mg x 4 days) on the plasma concentration profile of methylprednisolone.
90. Study AZM-NY-90-030: Preliminary study to evaluate the tolerability and the pharmacokinetics of azithromycin in HIV+ patients treated with zidovudine. Dated 17 June 1991.
91. Chave, JP, *et al.* Once-a-week Azithromycin in AIDS patients: Tolerability, Kinetics, and Effects on Zidovudine Disposition. *Antimicrobial Agents and Chemotherapy*, May 1992, Vol. 36, No. 5, p. 1013-1018.
92. Zithromax 3-Day Registration Dossier, containing 7 volumes:

Volume 1

Addendum to Pharmacotoxicology Expert Report

Additional Toxicology Information

Study WEL 90-252: A five-week oral toxicity study in neonatal beagle dogs

Volume 2

Clinical Expert Overview of Azithromycin in Children

Additional Clinical Pharmacology Information

Drug metabolism report (066-136): Study to evaluate the pharmacokinetics of azithromycin following oral administration of multiple doses of suspension to children with streptococcal pharyngitis.

A comparison of the pharmacokinetics of azithromycin in pediatric patients and adult healthy volunteers.

Study 220: An open assessment of the toleration, safety and pharmacokinetics of azithromycin after administration of multiple oral doses to children.

Volume 3

Additional Clinical Information

Study 397: A multicenter open comparative study of the efficacy, safety and toleration of azithromycin and erythromycin in the treatment of pediatric patients with acute pharyngitis due to group A beta-hemolytic streptococci.

Volume 4

Study 398: A multicenter open comparative study of the efficacy, safety and toleration of azithromycin and penicillin in the treatment of pediatric patients with acute pharyngitis due to group A beta-hemolytic streptococci.

Study 337: An open study to compare the efficacy, safety and toleration of azithromycin (3-day regimen) and Augmentin in the treatment of otitis media in children.

Volume 5

Study 394: A multicenter open comparative study of the efficacy, safety and toleration of azithromycin and amoxicillin in the treatment of pediatric patients with acute otitis media.

Study AZM-NY-90-006: A multicenter open comparative study of the efficacy, safety and toleration of azithromycin compared with amoxicillin/clavulanic acid (Augmentin) in the treatment of pediatric patients with acute otitis media.

Volume 6

Study 128: Azithromycin in the treatment of acute otitis media in children. A multicenter open-label trial employing amoxicillin/clavulanate potassium (Augmentin) as a comparative agent.

Study 395/396: A comparative study of the efficacy, safety and toleration of azithromycin and dicloxacillin or flucloxacillin in the treatment of pediatric patients with acute skin and/or soft tissue infections.

Volume 7

Study 321: An open study to compare the efficacy, safety and toleration of azithromycin and penicillin V in the treatment of bacterial pharyngitis in children.

Study 322: An open study to compare the efficacy, safety and toleration of azithromycin and Augmentin in the treatment of otitis media in children.

93. Study Report: Azithromycin (Zithromax)-Cyclosporin Interaction Study in Normal Volunteers, Prof. DeSchepper, PJ. Includes: Comments on Azithromycin-Cyclosporin Interaction Study from Dr Rapeport, WG, 1 February 1993 and Foulds, G, 16 February 1993.
94. CIOMS Reports of events attributed to interactions between azithromycin and digoxin, #9300410, RE18, RUS2763, 9302T14, and L-1A692.
95. Study 066-037: Phase I study to assess the effect of concomitant azithromycin therapy on the plasma concentrations and electrogram effects of terfenadine.
96. Update on hearing abnormalities in azithromycin therapy in patients with opportunistic infections.

97. CIOMS II: Safety Update I: Section 8.7 (August 1993). Liver toxicity with 4 case summaries of cholestatic hepatitis and respective CIOMS Suspect Adverse Reaction Reports.
98. CIOMS II: Safety Update II: Section 8.7 (December 1993). Liver toxicity with 1 case summary of cholestatic hepatitis and respective CIOMS Suspect Adverse Reaction Reports.
99. Safety Evaluation Risk Assessment Report on “Azithromycin and Photosensitivity”, 7 October 1994.
100. Safety Evaluation Risk Assessment Report on “Azithromycin and Terfenadine Drug Interaction”, 28 June 1996.
101. Post-Marketing Safety Review Report on “Azithromycin and Fatal Anaphylaxis” through 31 July 1996.
102. Post-Marketing Safety Review Report on “Azithromycin and Palpitations” through 30 January 1996.
103. Post-Marketing Safety Review Report on “Azithromycin and Tachycardia” through 30 January 1996.
104. Post-Marketing Safety Review Report on “Azithromycin and Dizziness” through 30 January 1996.
105. Post-Marketing Safety Review Report on “Azithromycin and Vertigo” through 30 January 1996.
106. Post-Marketing Safety Review Report on “Azithromycin and Seizures” through 30 January 1996.
107. Post-Marketing Safety Review Report on “Azithromycin and Headache” through 30 January 1996.
108. Post-Marketing Safety Review Report on “Azithromycin and Somnolence” through 30 January 1996.
109. Post-Marketing Safety Review Report on “Azithromycin and Paresthesia” through 30 January 1996.
110. Post-Marketing Safety Review Report on “Azithromycin and Anorexia” through 30 January 1996.
111. Post-Marketing Safety Review Report on “Azithromycin and Dyspepsia” through 30 January 1996.
112. Post-Marketing Safety Review Report on “Azithromycin and Constipation” through 30 January 1996.
113. Post-Marketing Safety Review Report on “Azithromycin and Asthenia” through 30 January 1996.
114. Post-Marketing Safety Review Report on “Azithromycin and Renal Adverse Events” through 30 January 1996.

115. Post-Marketing Safety Review Report on “Azithromycin and Liver Events” through 30 January 1996.
116. Post-Marketing Safety Review Report on “Azithromycin and Arthralgia” through 30 January 1996.
117. Post-Marketing Safety Review Report on “Azithromycin and Edema” through 30 January 1996.
118. Post-Marketing Safety Review Report on “Azithromycin and Urticaria” through 30 January 1996.
119. Post-Marketing Safety Review Report on “Azithromycin and Serious Skin Events” through 30 January 1996.
120. Post-Marketing Safety Review Report on “Azithromycin and Hearing Adverse Events” through 30 January 1996.
121. Post-Marketing Safety Review Report on “Azithromycin and Taste Disturbances” through 30 January 1996.
122. MAC Prophylaxis IRD, 21Dec95.
123. Worldwide Labeling Report on “Azithromycin and Aggressive Reaction” dated 9 June 1998.
124. Worldwide Labeling Report on “Azithromycin and Agitation” dated 9 June 1998.
125. Worldwide Labeling Report on “Azithromycin and Anxiety” dated 9 June 1998.
126. Worldwide Labeling Report on “Azithromycin and Hyperkinesia” dated 9 June 1998.
127. Worldwide Labeling Report on “Azithromycin and Moniliasis” dated 9 June 1998.
128. Worldwide Labeling Report on “Azithromycin and Nervousness” dated 9 June 1998.
129. Worldwide Labeling Report on “Azithromycin and Pruritus” dated 9 June 1998.
130. Worldwide Labeling Report on “Azithromycin and Pseudomembranous Colitis” dated 9 June 1998.
131. Worldwide Labeling Report on “Azithromycin and Taste Perversion” dated 9 June 1998.
132. Worldwide Labeling Report on “Azithromycin and Thrombocytopenia” dated 9 June 1998.
133. Worldwide Labeling Report on “Azithromycin and Tongue Discoloration” dated 9 June 1998.
134. Worldwide Labeling Report on “Azithromycin and Vaginitis” dated 9 June 1998.
135. Worldwide Labeling Report on “Azithromycin and Prothrombin Decrease” dated 9 June 1998.
136. Final Study Report: Protocol 066-328. An open, pilot study to assess the efficacy, toleration and safety of Azithromycin in the treatment of chancroid caused by *Haemophilus ducreyi*, dated 05 November 1994.

137. Final Study Report: Protocol 90-007. Single-dose Azithromycin for the treatment of chancroid: A randomized comparison with erythromycin, dated 3 November 1994.
138. Final Study Report: Protocol 066-120. Azithromycin in the treatment of chancroid. A multicenter open trial employing ceftriaxone as a comparative agent, dated 12 August 1994.
139. Safety Analysis Report on “Azithromycin and Hepatotoxicity” dated 13Feb98, compiled by S. Rohde, PhD.
140. Azithromycin in the Treatment of Streptococcal Pharyngitis Medical Expert Report prepared by Dr. A. Kolokathis with supportive references, dated 23 November 1999.
141. Safety Analysis Report on “Azithromycin and Overdosage” dated 4May98, compiled by S. Rohde, PhD.
142. Clinical Expert Report: Azithromycin Odonto-Stomatological Infections, Volume A, Pr. Guilbert, March 27, 2000.
143. Clinical Expert Report: Azithromycin for the Indication of Disseminated Mycobacterium Avium Complex (MAC) Disease. IRD Azithromycin in the Treatment of Disseminated Mac Infection, Volume 1, March 2000, p. 18-92.
144. Clinical Expert Report: Azithromycin IV (Intravenous) in the Treatment of Community Acquired Pneumonia and Pelvic Inflammatory Disease. IRD Azithromycin Powder for Solution for Infusion, Part I, Volume 1, August 2000, p. 33-88.
145. Study Report: Protocol 066-055. An Open Study of Azithromycin Serum Concentration Following Oral Administration of 250 mg Tablets With and Without Food. Abridged IRD Zithromax (Azithromycin) Tablets 250 mg, 500 mg, Volume 3.1, Part IV, December 1994, p. 1-68.
146. Final Study Report: Azithromycin Protocol AZM-F-96-001. Multicenter, Open Randomized, Comparative Trial of the Efficacy and Safety of Azithromycin 10 mg/kg or 20 mg/kg Daily for 3 Days and Penicillin V in the Treatment of Acute Streptococcal Pharyngitis in Children. Report Date: 4 January 2001.
147. Final Study Report: Azithromycin Protocol AZM-NY-92-021. A Multicenter, Double Blind, Comparative Study of the Efficacy, Safety and Toleration of Azithromycin and Penicillin V in the Treatment of Pediatric Patients with Acute Pharyngitis/Tonsillitis Due to Group A Beta-Hemolytic Streptococci. Report Date: 22 September 2000.
148. Final Study Report: Azithromycin Protocol R-0581. A Double-Blind, Double-Dummy, Multicenter, Randomized Trial of Single-Dose Azithromycin Versus Amoxicillin/ Clavulanate in the Treatment of Acute Otitis Media in Children Ages 6 Month to 12 Years. Report Date: 2 January 2001.
149. Final Study Report: Azithromycin Protocol AZM-NY-95-001. A Single Blind Comparative Study of the Efficacy, Safety and Toleration of Oral Single Dose Azithromycin Suspension 30 mg/kg, Oral Azithromycin Suspension 10 mg/kg/day for 3 Days and Intramuscular Single Dose

- Ceftriaxone (50 mg/kg) in the Treatment of Pediatric Patients with Documented Acute Otitis Media. Report Date: 1 December 2000.
150. Final Study Report: Azithromycin Protocol A0661014. A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin (Zithromax) Versus Amoxicillin/Clavulanate Potassium (Augmentin) in the Treatment of Acute Otitis Media in Children. Report Date: 13 December 2000.
 151. Final Study Report: Azithromycin Protocol A0661015. A Multicenter, Open Label, Non-Comparative Trial of a Single Dose of 30 mg/kg Azithromycin in the Treatment of Acute Otitis Media in Pediatric Subjects Undergoing Diagnostic Tympanocentesis. Report Date: 2 January 2001.
 152. Final Study Report: Protocol AZM-NY-90-008. An Open Study to Evaluate the Pharmacokinetics of Azithromycin when Administered to Subjects with Varying Degrees of Renal Impairment. Report Date: 28 September 1993.
 153. Cetirizine Study 93CK16-0624: A Multiple Dose Study to Evaluate the Pharmacokinetic and/or ECG Effects on Concomitant Administration of a Course of Azithromycin Therapy with Cetirizine (abstract), sNDA 07Feb2001.
 154. Dunn CJ and Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. *Drug Evaluation* 1996;51(3):483-505.
 155. Rapp RP. Pharmacokinetic and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced tissue activity and minimal drug interactions. *The Annals of Pharmacotherapy* 1998;32:785-793.
 156. Dresser GK, Spence JD and Bailey DG. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. *Drug Interactions* 2000;38(1):41-57.
 157. Watkins VS, Polk RE and Stotka JL. Drug Interactions of Macrolides: Emphasis on dirithromycin. *The Annals of Pharmacotherapy* 1997;31:349-356.
 158. Final Study Report: Azithromycin Protocol 066-092. The Effect of Azithromycin or Clarithromycin on the Pharmacokinetics of Atorvastatin in Healthy Subjects. Report Date: 26 August 1998.
 159. Azithromycin Study 066-086. A Study to Assess the Effect of Co-administration of a 1200 mg Dose of Azithromycin on the Pharmacokinetics of Fluconazole. IRD Azithromycin in the Treatment of Disseminated MAC Infection, Volume 1, March 2000.
 160. Azithromycin Study 066-085. A Study to Assess the Effect of a Single 1200 mg Dose of Azithromycin on the Pharmacokinetics of Indinavir. IRD Azithromycin in the Treatment of Disseminated MAC Infection, Volume 1, March 2000.
 161. Study No. AZM-MACK-94-004. Drug Interaction Study Between Midazolam and Macrolide Antibiotic. Open, Three-Way Crossover Study of the Single Dose Pharmacokinetics and Pharmacodynamics of Midazolam in Healthy Volunteers: With and Without Multiple Dose Pretreatment with Erythromycin or Azithromycin. 27 March 1995.

162. Azithromycin Study 066-094. The Effect of Azithromycin on the Pharmacokinetics of Nelfinavir in Healthy Volunteers. IRD Azithromycin in the Treatment of Disseminated MAC Infection, Volume 1, March 2000.
163. Final Study Report: Protocol 148-238. An Open, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Effects of Azithromycin (500 mg OD x 3 Days) on the Pharmacokinetics of a Single 100 mg Dose of Sildenafil. Report Date: 3 July 1998.
164. Greenblatt, DJ, *et al.* Inhibition of Triazolam Clearance by Macrolide Antimicrobial Agents: *In vitro* Correlates and Dynamic Consequences. *Clinical Pharmacology & Therapeutics*, September 1998, Volume 64, No. 3, p. 278-285.
165. Final Study Report: Protocol 066-088. A Study to Assess the Effect of a Single 1200 mg Dose of Azithromycin on the Pharmacokinetics of Trimethoprim-Sulfamethoxazole. Report Date: 19 February 1999.
166. Clinical Expert Report: Azithromycin for the Prevention of Disseminated Mycobacterium Avium Intracellulare Complex Disease in HIV-SeroPositive Patients. Abridged IRD Azithromycin (Zithromax) Tablets-600 mg in Prophylaxis Against Opportunistic Infections, Part I, Volume 1, December 1995, p. 1-33.
167. Worldwide Labeling Report: Hypotension and Azithromycin, dated 25Apr2001.
168. Worldwide Labeling Report: Syncope and Azithromycin, dated 25Apr2001.
169. Worldwide Labeling Report: Pancreatitis and Azithromycin, dated 25Apr2001.
170. Worldwide Labeling Report: Fatigue and Azithromycin, dated 25Apr2001.
171. Worldwide Labeling Report: Malaise and Azithromycin, dated 25Apr2001.
172. Azithromycin Study 066-077. Phase I Study to Evaluate the Pharmacokinetic Properties of Azithromycin After Multiple Oral Dosing of the Tablet Formulation in Asymptomatic HIV-Seropositive Subjects. IRD Azithromycin in the Treatment of Disseminated MAC Infection, Volume 1, March 2000.
173. Stability of Azithromycin Powder for Solution for Infusion. IRD Azithromycin Powder for Solution for Infusion, Part II, Volume 1, August 2000, p. 1-34.
174. Final Study Report: Azithromycin Protocol 066-038. Phase I Study to Assess the Effect of Concomitant Azithromycin Therapy on the Clinical Pharmacology of Zidovudine. Report Date: 13 December 1995.
175. Final Study Report: Protocol 066-040. Phase I Study to Assess the Effect of Concomitant Azithromycin therapy on the Clinical Pharmacology of Dideoxyinosine. Report Date: 24 July 1995.
176. Final Study Report: Protocol 066-074. Phase I Study to Evaluate the Pharmacokinetic Interaction Between Rifabutin and the Macrolides Azithromycin and Clarithromycin in Healthy Subjects. Report Date: 4 December 1995.

177. European Public Assessment Report (EPAR) for Efavirenz: Scientific Discussion. EMEA 2002, p. 1-30.
178. Azithromycin IRD. March 1990. Overall Clinical Summary; Section 3, Pharmacokinetics. p. 36-67.
179. Viskin S, *et al.* Drug-Induced *Torsades de Pointes*. Harrison's Online. The McGraw-Hill Companies. URL: <http://harrisons.accessmedicine.com/server-java/Arknoide/amed/harrisons/ex_editorials/ed12365_p01.html> last modified 07 Apr 2001 (accessed 24 Mar 2003).
180. Worldwide Labeling Safety Report. QT-Related Events and Azithromycin, dated 13 Mar 2003.
181. Pollak PT, MacNeil DM. Azithromycin-Theophylline Inhibition-Induction Interaction. Clinical Pharmacology & Therapeutics. Feb 1999. 69(2): 144.
182. One Year Azithromycin Periodic Safety Update Report October 2004.
183. Module 2.4 Nonclinical Overview, June 17, 2005, Azithromycin Prolonged Release Granules CTD.
184. Risk Management Strategy Report: Azithromycin and Taste/Smell Loss, July 6, 2005.
185. Letter from FDA issued 29 September 2006 (received 10 October 2006).
186. Wysowski DK. Increase in deaths related to enterocolitis due to *Clostridium difficile* in the United States, 1999-2002. Public Health Reports 2006; 121:361-362.
187. *Clostridium difficile*: deaths increase in 2005. Deaths: Office for National Statistics, England and Wales. Available at: <http://www.statistics.gov.uk/cci/nugget.asp?id=1735> Accessed May, 2007.
188. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, *et al.* An epidemic, toxin gene-variant strain of *Clostridium difficile*. N Engl J Med 2005; 353:2433-2441.
189. Loo VC, Poirier L, Miller MA, Oughton M, Libman, MD, Michaud S, *et al.* A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449.
190. Chernak E, Johnson CC, Weltman A, McDonald LC, Wiggs L, Killgore G, *et al.* Severe *Clostridium difficile*-associated disease in populations previously at low risk---four states, 2005. Morbidity and Mortality Weekly Report 2005; 54(47); 1201-1205.
191. Pepin J, Valiquette L, Alary M-E, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-472.
192. Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. *Clostridium difficile* colitis: an increasingly aggressive iatrogenic disease? Arch Surg 2002; 137:1096-1100.
193. McCusker ME, Harris AD, Perencevich E, Roghmann M-C. Fluoroquinolone use and *Clostridium-difficile* associated diarrhea. Emerging Infect Dis 2003; 9:730-733.

194. Thomas C, Stevenson M, Williamson DJ, Riley TV. *Clostridium difficile*-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002; 35:1457-1462.
195. D. Levy *et al.*, Antibiotics and *C. difficile* Diarrhea in the Ambulatory Care Setting, Clin. Therapeutics, 2000; 22 (1): 91-102.
196. G. Cote and A. Buchman, Antibiotic-associated Diarrhea, Expert Opin. Drug Saf. (2006) 5(3):361-372.
197. Kuijper E., *et al.*, Emergence of *Clostridium difficile*-associated disease in North America and Europe, Clin Microbiol Infect 2006; 12 (Suppl. 6): 2–18.
198. Gifford AH and Kirkland KB, Risk factors for *Clostridium difficile*-associated diarrhea on an adult hematology-oncology ward, Eur J Clin Microbiol Infect Dis (2006) 25:751–755.
199. Risk Management Strategy Report: Azithromycin and Hypoaesthesia, 13 December 2005.
200. EMEA Volume 3 B Guidelines, Excipients in the label and package leaflet of medicinal products for human use, July 2003.
201. Azithromycin Prolonged-Release Granules for Oral Suspension (Azithromycin SR) Module 3.2.P.1. Description and Composition of the Drug Product. 26 Aug 2008.
202. Azithromycin SR Module 2.5 Clinical Overview. 20 Feb 2007.
203. Final Study Report: Protocol A0661107. An Open-Label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Single 2-Gram Oral Dose of an Experimental Azithromycin Dihydrate Microspheres Sustained Release Formulation (Zithromax SR) Under Fasting and Fed Conditions in Healthy Volunteers.
204. Final Study Report: Protocol A0661114. An Open-Label, Randomized, 2-Way Crossover Study to Evaluate the Effect of a Standard Meal on the Pharmacokinetics of Azithromycin Sustained Release Oral Powder for Suspension in Healthy Volunteers.
205. Zmax SPC. 12 March 2007.
206. Final Study Report:A0661115. An Open-Label, Randomized, 2-Way Crossover Study to Evaluate the Effect of Maalox[®] on the Pharmacokinetics of Azithromycin Sustained Release Oral Powder for Suspension in Healthy Volunteers
207. Azithromycin SR. Module 2.7, Section 2.7.4, Summary of Clinical Safety. Table 16. 05 Dec 2005.
208. Azithromycin SR, Module 2.7, Section 2.7.4, Summary of Clinical Safety. Appendix I, Table 8.1. 05 Dec 2005.
209. Azithromycin SR. Module 2.7, Section 2.7.4, Summary of Clinical Safety. Appendix I, Table 10.1. 05 Dec 2005.

210. Final Study Report: Protocol A0661124. An Open-Label, Randomized, 2-Way Crossover Study to Evaluate the Bioequivalence of a Single 2-Gram Dose of Azithromycin Sustained Release Oral Powder for Suspension Between the ICH Drug Supplies and the Phase 3 Study Drug Supplies in Healthy Adult Subjects.
211. Final Study Report: Protocol A0661186. Phase 1, Observer-Blind, Randomized, Parallel Study to Evaluate the Gastrointestinal Tolerability of 2 g Doses of Two Different Sustained-Release Formulations of Azithromycin Compared to a Single 2 g Dose of the Commercial Formulation in Healthy Adult Volunteer.
212. Final Study Report: Protocol A066-087. A crossover Design Study of Serum and WBC Pharmacokinetics of 1500 mg Oral Azithromycin when given over a Five Day or a Three-Day Period in Normal Subjects.
213. Final Study Report: Protocol A0661084. An Open-Label, Randomized, Crossover Pilot Study Evaluating the Pharmacokinetics and Tolerability of a Single 2 gram Dose of a Sustained-Release Formulation of Azithromycin with and without Magnesium Hydroxide Compared to a Single 2 gram Dose of the Commercial Formulation Under Fasted Conditions in Healthy Adult Volunteers
214. ZITHROMAX[®] (azithromycin tablets and azithromycin for oral suspension) USPI. June 2010.
215. Azithromycin Prolonged Release Granules Module 3, June 17, 2005, CMC section.
216. Clinical Overview. Azithromycin and P-gp. 24 August 2010.
217. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. <http://www.eucast.org>.
218. Clinical and Laboratory Standards Institute. *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria*, 3rd ed. CLSI guideline M45. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
219. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing*. 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
220. Azithromycin SR. Module 2.3, Quality Overall Summary. 29 Aug 2008.
221. Pfizer. Investigator's Brochure. Azithromycin Sustained Release Addendum. April 2006.
222. Final Study Report. Study 9: The Protein Binding of Azithromycin in Human, Dog, Rat, and Mouse Serum.
223. Clinical Overview for Azithromycin Core Data Sheet Changes. December 2011.
224. 2.5 Clinical Overview for Azithromycin CDS changes. December 2011.
225. 2.5 Clinical Overview for Azithromycin justification for label update to section 4.4 special warnings and precautions and section 5.1 pharmacodynamic properties with reference to QT prolongation-April 2013.

226. 2.5 Clinical Overview for Azithromycin- Oral update to Posology in relation to Gonorrhoea- May 2013.
227. 2.5 Clinical Overview for Azithromycin- Oral update to Interaction with Antacids and Ergot derivatives – June 2013
228. 2.5 Clinical Overview for Azithromycin-Core Data Sheet Update Section 4.4 ‘Warnings and Precautions for Use’ and Section 4.8 ‘Undesirable Effects’ For the Risk of DRESS’ – December 2015.
229. Periti P, Mazzei T, Mini E, *et al.* Pharmacokinetic Drug Interactions of Macrolides Clin. Pharmacokinet 1992;23(2): 106-131.
230. 2.5 Clinical Overview for Azithromycin CDS update with Infantile Hypertrophic Pyloric Stenosis (IHPS) November 2015.
231. 2.5 Clinical Overview Azithromycin Core Data Sheet Update- Addition of Myasthenia Gravis to Section 4.4 ‘Special Warnings and Precautions for Use’; April 2016.
232. 2.5 Clinical Overview for Azithromycin CDS Update - Addition of AGEP ADR, March 2017.
233. 2.5 Clinical Overview for Azithromycin CDS Update - Section 4.6 Lactation Update, February 2018.
234. 2.5 Clinical Overview for Azithromycin CDS Update - Correction of Frequency for the DRESS ADR, February 2018.
235. 2.5 Clinical Overview for Azithromycin CDS Update - Updates to Section 4.5, April 2018

Document Approval Record

Document Name: LPD Azithromycin - Zetamax (Pakistan)

Document Title: LPD Azithromycin - Zetamax (Pakistan)

Signed By:	Date(GMT)	Signing Capacity
Patel, Bushra Muzamil	30-May-2018 07:30:53	Regulatory Affairs Approval